INHERITED CANCER GENETICS · UK public procurement notice

Single supplier – technical reasons The requirement relates to a highly specialised clinical service for inherited cancer genetic testing, which requires specific technical capability, accredited laboratory processes, and integration with existing clinical pathways. The identified supplier has the necessary infrastructure, validated methodologies, and established interfaces with the All Wales Medical Genomics Service (AWMGS), enabling continuity of testing, reporting, and data management. These technical requirements cannot be readily replicated by alternative suppliers within the required timeframe without significant disruption. Furthermore, the supplier’s ability to deliver within existing turnaround times, manage current demand, and support backlog recovery is dependent on proprietary systems, validated workflows, and specialist expertise. Transitioning to an alternative supplier would necessitate duplication of validation processes, interface development, and clinical assurance activity, introducing unacceptable operational and clinical risk. Single supplier – unique work of art or performance (proprietary justification) The service provision is considered proprietary in nature due to the supplier’s established integration within the current service model, including embedded processes, reporting mechanisms, and clinical pathways specific to AWMGS requirements. The supplier is already delivering testing services aligned to the Health Board’s specifications, with proven performance in managing complex and high-volume diagnostic workloads. Their service includes unique elements such as established data flows, validated testing protocols, and familiarity with Welsh clinical pathways, which collectively form a bespoke service offering that is not readily transferable. Any change in supplier would require significant revalidation of testing processes, redevelopment of interfaces, and onboarding of clinical pathways, which would disrupt service delivery and delay patient diagnosis. This establishes the supplier as the only provider capable of delivering the required service without interruption, therefore justifying a sole supplier award on the basis of proprietary service delivery.